Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Villejuif – page 274

3 340 clinical trials in Villejuif, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Villejuif at a glance
3 340
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 340 trials in Villejuif

Open in trial search

Neuroblastoma+5

Not recruiting

Study of Nivolumab with Chemotherapy for Children and Teenagers with Refractory or Relapsing Solid Tumors or Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Capecitabine
  • Sponsor:Centre Oscar Lambret

Neoplasm

Not recruiting

Study of MCLA-129 with Chemotherapy and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Genmab A/S

Cholangitis sclerosing

Not recruiting

Study on Norucholic Acid for Treating Primary Sclerosing Cholangitis in Patients

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Norucholic Acid
  • Sponsor:Dr. Falk Pharma GmbH

Ovarian cancer+1

Not recruiting

Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Arcagy Gineco

Renal cancer metastatic

Not recruiting

Study on Cabozantinib, Nivolumab, and Ipilimumab for Patients with Advanced or Metastatic Kidney Cancer Who Have Not Received Prior Treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Staphylococcal infection

Not recruiting

Study on Dalbavancin and Rifampicin for Treating Prosthetic Joint Infections in Patients with Hip, Knee, and Shoulder Replacements

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dalbavancin
  • Sponsor:Centre Hospitalier Universitaire De Nice

Hepatocellular carcinoma

Not recruiting

Study of lenvatinib treatment benefits in patients with non-resectable liver cancer (hepatocellular carcinoma) who are on liver transplant waiting list after unsuccessful TACE therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Assistance Publique Hopitaux De Paris

Sinusitis bacterial+1

Not recruiting

Study on Azithromycin for Treating Chronic Sinusitis in Adults

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azithromycin
  • Sponsor:Centre Hospitalier Intercommunal Creteil

Peritoneal sarcoma+2

Not recruiting

Study of mirvetuximab soravtansine compared to standard chemotherapy in women with platinum-resistant advanced ovarian cancer with high folate receptor expression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Immunogen Inc.

Chronic hepatitis B

Not recruiting

Study on the Effects of Peginterferon Alfa-2a, Tobevibart, and Elebsiran in Patients with Chronic Hepatitis B Infection

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Tenofovir Disoproxil
  • Sponsor:Vir Biotechnology Inc.

Renal cell carcinoma

Not recruiting

Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Aveo Pharmaceuticals Inc.

Renal cell carcinoma

Not recruiting

Study on Durvalumab and Tremelimumab for Patients with Kidney Cancer at Risk of Recurrence After Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:University College London

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Villejuif

What the registry says about research in the country

01 Oncology - Head and Neck Cancer

Innovative research focusing on locally advanced head and neck squamous cell carcinoma treatments, including novel therapies combined with radiotherapy and immunotherapy approaches.

  • NBTXR3 with radiotherapy
  • EGFR-ADC therapy combinations
  • HPV-positive oropharyngeal cancer
02 Gastrointestinal Oncology

Studies targeting various digestive system cancers, with particular focus on pancreatic adenocarcinoma and advanced gastric cancer treatments.

  • Anti-CEACAM5 ADC therapy
  • Sotorasib combinations
  • Novel gastrointestinal cancer treatments
03 Hematologic Malignancies

Cutting-edge research in multiple myeloma treatment, exploring new combination therapies and maintenance approaches.

  • Elranatamab-lenalidomide therapy
  • Belantamab mafodotin combinations
  • T-cell lymphoma treatments
04 Lung Cancer Research

Comprehensive studies in both non-small cell lung cancer and small cell lung cancer, investigating targeted therapies and immunotherapy combinations.

  • Novel antibody-drug conjugates
  • Microbiome-based approaches
  • Targeted therapy combinations
05 Advanced Solid Tumors

Broad-spectrum research investigating novel treatments for metastatic solid tumors, including innovative therapeutic approaches and combination strategies.

  • PARG inhibitor studies
  • Targeted molecular therapies
  • Immunotherapy combinations
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.